Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO.

Cancer Deprescribing Multidisciplinary management Older adult Polypharmacy

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 02 07 2023
revised: 25 08 2023
accepted: 30 08 2023
medline: 18 9 2023
pubmed: 4 9 2023
entrez: 3 9 2023
Statut: ppublish

Résumé

Optimizing anticancer treatment and medication therapy in older patients with cancer requires a multidisciplinary approach, with a strong collaboration between geriatricians, oncologists and pharmacists. While all patients can benefit, some clinical situations seem to be high-priority. Careful attention should be given to patients with cardiovascular comorbidities and/or diabetes, which are prone to decompensate during anticancer treatment and often involve multiple medications. Another great concern is the risk of falls, closely related to polypharmacy, hence the need for a comprehensive medication review. Managing the pharmacological treatment of depression is also challenging and require shared expertise. Finally, pharmacists can prove valuable in situations of adherence difficulties or use of complementary medicines. Collaborative practice should begin at initiation of anticancer treatment and continue throughout the care pathway, as continuous reassessment is essential. Although the integration of pharmacists in multidisciplinary teams is often challenged by funding, collaborative should still be strongly encouraged.

Identifiants

pubmed: 37660933
pii: S1040-8428(23)00205-6
doi: 10.1016/j.critrevonc.2023.104117
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104117

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Chloé Herledan (C)

Société Française de Pharmacie Oncologique (SFPO), France; Department of Pharmacy, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre-Bénite, France and EA 3738 CICLY, Lyon 1 University, Oullins, France. Electronic address: chloe.herledan@chu-lyon.fr.

Anne Toulemonde (A)

Société Française de Pharmacie Oncologique (SFPO), France; Department of Pharmacy, Lille University Hospital, Lille, France.

Anne-Laure Clairet (AL)

Société Française de Pharmacie Oncologique (SFPO), France; Department of Pharmacy, Centre Hospitalier Universitaire de Besançon, Besançon, France and INSERM, EFS BFC, UMR 1098, Interaction Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, France.

Mathieu Boulin (M)

Société Française de Pharmacie Oncologique (SFPO), France; Department of Pharmacy, Dijon University Hospital and EPICAD LNC UMR 1231, University of Burgundy & Franche Comte, Dijon, France.

Claire Falandry (C)

Société Francophone d'Oncogériatrie (SoFOG), France; Institut du Vieillissement, Hospices Civils de Lyon, Lyon, France and Laboratoire CarMeN, INSERM U1060/ INRAE U1397/ Université Lyon 1, Université de Lyon, Pierre-Bénite, France.

Laure De Decker (L)

Société Francophone d'Oncogériatrie (SoFOG), France; Clinical Gerontology Department, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France.

Catherine Rioufol (C)

Société Française de Pharmacie Oncologique (SFPO), France; Department of Pharmacy, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre-Bénite, France and EA 3738 CICLY, Lyon 1 University, Oullins, France.

Arnaud Bayle (A)

Société Francophone d'Oncogériatrie (SoFOG), France; Université Paris Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin Bicêtre, Paris, France and Bureau biostatistique et épidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Nicolas Bertrand (N)

Société Francophone d'Oncogériatrie (SoFOG), France; Université de Lille, CHU Lille, ULR 2694 METRICS, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH